Axtria Thought Leadership
Executive insights and perspectives on the Life Sciences industry
White Paper
Why The COVID-19 Recession Is Different And More Dangerous Than The Great Recession
The need for empirical analysis of these dynamics is critical to the successful operation of pharma companies. Pharma executives need to take note and accordingly make plans not on ...
White Paper
What Analytical Techniques Should Pharma Companies Implement To Forecast COVID-19 Effects?
This white paper reviews the importance of companies conducting subnational econometric analysis on drug demand estimation and forecasting. Companies need to understand these effec ...
White Paper
What Is At Stake For The Pharma Industry From The Upcoming 2020 Elections?
The upcoming November 2020 presidential and congressional elections represent a key event for the pharma industry. Current industry focus is on COVID-19, the effects from public po ...
Report
Specialty Pharmacy: A Unique And Growing Industry
This point of view report explores the changing dynamics of the specialty pharmacy industry and highlights implications for pharmaceutical companies in terms of demand generation, ...
White Paper
Will The Pharma Industry’s Response To COVID-19 Positively Affect Its Image? A Commentary
The pharmaceutical industry has stepped up in a big way in search of vaccines and effective treatments for COVID-19. One reference cited at least 250 drugs and 95 vaccines under in ...
White Paper
Effects Of A Resurgence In COVID-19 Cases On Future Pharmaceutical Business Planning
Fears have arisen regarding a resurgence in COVID-19 cases. Numerous factors could be contributing to a resurgence in COVID-19 cases. Some suggest it is because more tests are bein ...
Report
The Power Of Digital Technologies In Transforming Clinical Trials
Clinical trials are becoming more complex as pharmaceutical companies focus their research and development efforts on treatments for rare diseases and personalized medicine, and on ...
White Paper
COVID-19 Recession Effects On Pharmaceutical-Related Patient Health Outcomes
This white paper investigates the research framework to model the expected effects on the decline in health outcomes caused by a decrease in the quantity and quality of pharmaceuti ...
White paper
Should Pharmaceutical Incentive Compensation Plans Cap At-Risk Sales Rep Compensation?
This white paper looks at a simple but important research question – why do pharma companies have incentive compensation (IC) plans that cap their at-risk sales rep compensation? ...
